TheraRadar

Kyntra Bio

Pre-Approval PRO BETA
36
Total Trials
16
Phase 3
16
Phase 2
1
Recruiting
388
Score

Pipeline by Phase

Phase 3
16
Phase 2
16
Phase 1
5

Therapeutic Focus

Anemia Idiopathic Pulmonary Fibrosis Duchenne Muscular Dystrophy Chemotherapy Induced Anemia Chronic Kidney Disease

Clinical Trials (36)

NCT03941093 Phase 3 COMPLETED

Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer

Started: 5/10/2019

NCT03955146 Phase 3 TERMINATED

Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Started: 6/18/2019

NCT04632940 Phase 3 TERMINATED

Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD

Started: 3/3/2021

NCT04419558 Phase 3 TERMINATED

Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Started: 9/30/2020

NCT03263091 Phase 3 TERMINATED

Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden

Started: 1/29/2018

NCT04371666 Phase 3 TERMINATED

Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD)

Started: 8/10/2020

NCT05301517 Phase 3 COMPLETED

A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies

Started: 3/16/2022

NCT04410198 Phase 3 COMPLETED

Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis Participants

Started: 5/26/2020

NCT04484857 Phase 3 COMPLETED

Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants

Started: 7/22/2020

NCT04621331 Phase 3 WITHDRAWN

Investigating the Efficacy, Safety and PK of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD

Started: 5/23/2022

NCT02273726 Phase 3 COMPLETED

Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis

Started: 1/15/2015

NCT02052310 Phase 3 COMPLETED

Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants

Started: 2/11/2014

NCT01750190 Phase 3 COMPLETED

A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis

Started: 11/5/2012

NCT02652806 Phase 3 COMPLETED

FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease

Started: 12/1/2015

NCT02652819 Phase 3 COMPLETED

FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease Not on Dialysis

Started: 12/1/2015

NCT06842498 Phase 2 RECRUITING

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Started: 2/22/2026

NCT02606136 Phase 2 TERMINATED

Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

Started: 1/4/2016

NCT03303066 Phase 2 COMPLETED

Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS)

Started: 6/6/2018

NCT04432298 Phase 2 TERMINATED

Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease

Started: 6/20/2020

NCT04076943 Phase 2 COMPLETED

Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia

Started: 8/20/2019

NCT01244763 Phase 2 COMPLETED

Study of Roxadustat in Non-Dialysis Chronic Kidney Disease Participants With Anemia

Started: 10/29/2010

NCT01147666 Phase 2 COMPLETED

Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis

Started: 5/17/2010

NCT01414075 Phase 2 COMPLETED

Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment

Started: 7/21/2011

NCT01630889 Phase 2 COMPLETED

Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With Dialysis and Non-Dialysis Chronic Kidney Disease

Started: 5/18/2012

NCT01890265 Phase 2 COMPLETED

Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Started: 7/30/2013

NCT01262001 Phase 2 COMPLETED

Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis

Started: 3/1/2011

NCT00913393 Phase 2 TERMINATED

Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy

Started: 2/1/2009

NCT01217632 Phase 2 TERMINATED

A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection

Started: 8/1/2010

NCT01599507 Phase 2 COMPLETED

Study of FG-4592 in Subjects With Chronic Kidney Disease in China

Started: 12/1/2011

NCT01596855 Phase 2 COMPLETED

Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China

Started: 9/1/2011

NCT02210559 Phase 1 COMPLETED

A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer

Started: 7/31/2014

NCT00754143 Phase 1 COMPLETED

Phase 1 Study of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropathy

Started: 3/1/2008

NCT00782561 Phase 1 TERMINATED

Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)

Started: 4/1/2008

NCT01181245 Phase 1 COMPLETED

A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer

Started: 12/1/2008

NCT01376063 Phase 1 COMPLETED

Study to Investigate the Interaction Between FG-4592 and Rosiglitazone in Healthy Adult Subjects

Started: 3/1/2010

NCT04059913 Phase 4 COMPLETED

Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia in Dialysis Participants With Chronic Kidney Disease

Started: 6/11/2019

Drug Candidates

FG-3246 Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX Pamrevlumab Placebo Corticosteroids Roxadustat SEPO® FG-4592 FG-3019
Activity Status: Active
Last Trial Started: 2/22/2026
Last Trial Ended: 6/11/2024
Trials (12 months): 1
Completed Trials: 24
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.